Skip to content
AnalystLens

IDEXX Laboratories Annual Report, Year Ended Dec 31, 2010

Filing Date
Filed February 22, 2011
Period End
December 31, 2010
Security
IDXX
One revenue dollarkept$0.13
In the record · 2016–202610-K1110-Q338-K98

IDXX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.

  1. FY2016 annual report10-K · Feb ’17Feb ’17
  2. Leadership change8-K · Oct ’19Oct ’19
  3. Material agreement8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Jan ’26Jan ’26

Summary

Summary of the 10-K filed February 22, 2011. Cited figures are marked; the original filing is the authoritative source.

IDEXX Laboratories' 10-K for fiscal 2010 (filed February 22, 2011) shows a company that grew revenue 7.0% to $1.103 billiona, with 6.3% organic growth, and expanded operating income 15.9% to $203.9 million.

Growth was led by the Companion Animal Group (CAG), which generated $905.7 millionb (82% of revenue) and drove most of the increase through reference laboratory services (+10.5%), practice information systems and digital radiography (+15.6%), and instruments and consumables (+6.5%). Rapid assay sales were roughly flat, and the Water and Livestock & Poultry Diagnostics segments grew modestly. Gross margin improved to 52.4% from 51.0%, while operating expenses held at 34.0% of revenue.

Diluted EPS rose to $2.37c from $2.01. Cash generation and capital returns were strong. Operating cash flow was $178.8 million, and cash and investments ended the year at $156.9 million, up from $106.7 million.

The company repurchased 2.5 million shares for $143.1 milliond, and total debt was $133.3 million, almost entirely the $129.0 million Credit Facility, which carries a leverage covenant of 3-to-1. Management expects 2011 capital expenditures of about $45 million and says it has never paid a cash dividend and has no plans to do so. Key risks flagged in the filing include the U.S. Federal Trade Commission investigation into companion animal pricing and marketing practices and a parallel U.K.

Office of Fair Trading inquiry, both of which management believes do not violate antitrust law. Other risks include customer concentration (Butler Schein accounted for 9% of revenue), reliance on sole-source suppliers such as Ortho for chemistry slides, the expiry of a key FIV/FeLV patent in June 2009, weak pet-visit volumes from the economy, and rising competition from Abaxis and Antech. International sales accounted for 41% of revenue.

Key Highlights

  1. Revenue rose 7.0% to $1,103.4 million in 2010 (6.3% organic), led by CAG, which grew 7.4% to $905.7 million.
  2. Reference laboratory services grew 10.5% to $329.7 million, driven by higher testing volume from new customer acquisitions, while rapid assay revenue slipped 0.4% on price competition.
  3. Gross margin expanded to 52.4% from 51.0%, and operating income rose 15.9% to $203.9 million (18.5% of revenue).
  4. Diluted EPS increased to $2.37 from $2.01, supported by a 4.0% reduction in diluted share count from buybacks.
  5. Operating cash flow was $178.8 million; the company repurchased $143.1 million of stock (2.5 million shares) and ended the year with $156.9 million in cash and investments.
  6. Total debt rose to $133.3 million, almost entirely drawn on a $200 million revolving Credit Facility, which had $70.0 million of remaining availability.
  7. The FTC and U.K. OFT are investigating companion animal pricing and marketing practices; management says it is cooperating and does not expect a material adverse effect.

Follow one dollar

Of each $1.00 of revenue in FY2010, IDEXX Laboratories kept $0.13.

  1. Revenue$1.10B100.0%
  2. Cost of revenue−$524.8M47.6%
  3. Gross profit$578.6M52.4%
  4. Operating costs−$374.7M34.0%
  5. Operating income$203.9M18.5%
  6. Interest, other & tax−$62.6M5.7%
  7. Net income$141.3M12.8%
Computed from 10-KFY2010filed February 22, 2011Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2010 revenue went

$1.10B
  • Cost of revenue: $524.8M, 48% of revenue
  • Other operating costs: $306.1M, 28% of revenue
  • Net income: $141.3M, 13% of revenue
  • R&D: $68.6M, 6.2% of revenue
  • Interest, other & tax: $62.6M, 5.7% of revenue

Kept 13% as net income

Full revenue history →

Financial Statements

FY2010 against FY2009

Line itemFY2010FY2009Change
Revenue$1.10B$1.03B+7.0%
Cost of Revenue$524.77M$505.35M+3.8%
Gross Profit$578.62M$526.28M+9.9%
R&D Expenses$68.60M$65.12M+5.3%
Operating Income$203.88M$175.97M+15.9%
Interest Expense$2.42M$1.92M+26.0%
Net Income$141.28M$122.22M+15.6%
EPS (Basic)$1.23$1.04+17.8%
EPS (Diluted)$1.19$1.00+17.9%
Shares Outstanding (Basic)115.43M117.62M−1.9%
Shares Outstanding (Diluted)119.12M121.36M−1.9%

Frequently Asked Questions

  1. What drove IDEXX's revenue growth in 2010?

    Most of the growth came from the Companion Animal Group. Reference laboratory services grew 10.5% on higher testing volume and some price increases, instruments and consumables grew 6.5% on Catalyst Dx and ProCyte Dx placements, and practice information systems and digital radiography grew 15.6% as veterinarians transitioned from film to digital. Rapid assay sales were essentially flat, and Water, Livestock & Poultry, and Other segments grew modestly.

  2. What are the main regulatory and legal risks?

    The FTC has an open investigation under Section 5 of the FTC Act into companion animal pricing, marketing, and possible exclusive dealing or tying arrangements, and the U.K. OFT is investigating whether IDEXX foreclosed the supply of companion animal diagnostic testing services. Management believes its practices are lawful and that any required changes would not be materially adverse. The company has not recorded a loss contingency because a loss is neither probable nor reasonably estimable.

  3. How concentrated is IDEXX's customer and supplier base?

    Butler Schein Animal Health Supply accounted for 9% of 2010 revenue and 4% of net receivables. Many instruments, consumables, and components come from sole or single-source suppliers, most notably Ortho-Clinical Diagnostics for VetTest and Catalyst Dx chemistry slides, under agreements that run to 2025. International sales were 41% of revenue, and the company manufactures most of its companion animal products at a single facility in Westbrook, Maine.

  4. Is IDEXX returning cash to shareholders?

    Yes, primarily through share repurchases. In 2010 the company bought back 2.5 million shares for $143.1 million under a 44 million-share authorization, with 3.8 million shares remaining. It has never paid a cash dividend and has no present intention to do so. Management frames the buybacks as a favorable investment and also as a way to offset dilution from share-based compensation.